Holen Sie sich die Stockscreener-App
0.15
0.66%
-0.001
Handel nachbörslich:
.16
0.01
+6.67%
Schlusskurs vom Vortag:
$0.151
Offen:
$0.1502
24-Stunden-Volumen:
864.76K
Relative Volume:
0.84
Marktkapitalisierung:
$5.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-51.06M
KGV:
-0.1087
EPS:
-1.38
Netto-Cashflow:
$-40.03M
1W Leistung:
-17.22%
1M Leistung:
-34.73%
6M Leistung:
-81.41%
1J Leistung:
-74.11%
1-Tages-Spanne:
$0.14
$0.1543
1-Wochen-Bereich:
$0.1315
$0.1828
52-Wochen-Spanne:
$0.1315
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Firmenname
Viracta Therapeutics Inc
Sektor
Branche
Telefon
858-400-8470
Adresse
2533 S COAST HWY 101, CARDIFF
Vergleichen Sie VIRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VIRX | 0.15 | 5.80M | 0 | -51.06M | -40.03M | -1.38 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Eingeleitet | SVB Leerink | Outperform |
| 2021-03-25 | Eingeleitet | Evercore ISI | Outperform |
Viracta Therapeutics Inc Aktie (VIRX) Neueste Nachrichten
Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World
VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Sunesis: Q3 Earnings Snapshot - mySA
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Viracta Cuts Workforce 42%, Narrows Focus on PTCL Drug as Cash Runway Tightens | VIRX Stock News - StockTitan
Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech
Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR
Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter
VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK
Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com
Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com Canada
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times
Viracta Therapeutics Announces Reprioritization of - GlobeNewswire
Viracta (VIRX) Cuts 42% of Workforce, Restructures Board Amid Strategic Shift | VIRX Stock News - StockTitan
Viracta Therapeutics Restructures to Focus on Nana-val Program - TipRanks
Pharma takes aim at a wily foe — the Epstein-Barr virus - Yahoo Finance
T-cell Lymphoma Market Segments Analysis Report 2024-2031 - InsightAce Analytic
Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Peripheral T-Cell Lymphoma Market Expected to Experience Major - openPR
Head and Neck Cancer Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India
Head and Neck Cancer Market to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR - WhaTech
Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter
The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle
Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News
Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News
Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News
Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News
Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com
Here's Why Sunesis (VIRX) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Perhaps timely catching Viracta Therapeutics Inc (VIRX) would be a good idea - SETE News
Biopharma Layoff Tracker 2024: Lykos, Galera, Grail and More Cut Staff - BioSpace
Examining Viracta Therapeutics Inc (VIRX) stock is warranted - US Post News
Viracta Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Stock Surge: Viracta Therapeutics Inc (VIRX) Closes at 0.31, Marking a -11.76 Increase/Decrease - The Dwinnex
Viracta Therapeutics (NASDAQ:VIRX) PT Lowered to $4.00 - Defense World
Viracta Therapeutics (NASDAQ:VIRX) Downgraded by SVB Leerink to “Market Perform” - Defense World
What is Viracta Therapeutics Inc (VIRX) Stock Return on Shareholders’ Capital? - SETE News
Viracta Therapeutics stock PT lowered by RBC amid pipeline strategy shift - Investing.com Canada
Viracta reports progress in PTCL treatment trial By Investing.com - Investing.com Australia
Sunesis: Q2 Earnings Snapshot - San Antonio Express-News
Viracta reports progress in PTCL treatment trial - Investing.com
Finanzdaten der Viracta Therapeutics Inc-Aktie (VIRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):